Journal Thoracic Oncology
WCLC2016-Abstract-Book_vF-WEB_revNov17-1
WCLC2016-Abstract-Book_vF-WEB_revNov17-1
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Abstracts <strong>Journal</strong> of <strong>Thoracic</strong> <strong>Oncology</strong> • Volume 12 Issue S1 January 2017<br />
without surgical resection for stage III non-small-cell lung cancer: a phase<br />
III randomised controlled trial. Lancet. 2009;374:379-86. [2] Pless M, Stupp<br />
R, Ris HB, Stahel RA, Weder W, Thierstein S, et al. Induction chemoradiation<br />
in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.<br />
Lancet. 2015;386:1049-56. [3] Aupérin A, Le Péchoux C, Rolland E, Curran WJ,<br />
Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential<br />
radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol.<br />
2010;28:2181-90. [4] Collaud S, Fadel E, Schirren J, Yokomise H, Bolukbas S,<br />
Dartevelle P, et al. En Bloc Resection of Pulmonary Sulcus Non-small Cell Lung<br />
Cancer Invading the Spine: A Systematic Literature Review and Pooled Data<br />
Analysis. Ann Surg. 2015;262:184-8. [5] Rusch VW. Management of Pancoast<br />
tumours. Lancet Oncol. 2006;7:997-1005. [6] De Leyn P, Dooms C, Kuzdzal<br />
J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for<br />
preoperative mediastinal lymph node staging for non-small-cell lung cancer.<br />
Eur J Cardiothorac Surg. 2014;45:787-98. [7] Friedel G, Budach W, Dippon J,<br />
Spengler W, Eschmann SM, Pfannenberg C, et al. Phase II trial of a trimodality<br />
regimen for stage III non-small-cell lung cancer using chemotherapy as<br />
induction treatment with concurrent hyperfractionated chemoradiation with<br />
carboplatin and paclitaxel followed by subsequent resection: a single-center<br />
study. J Clin Oncol. 2010;28:942-8. [8] Hancock J, Rosen J, Moreno A, Kim AW,<br />
Detterbeck FC, Boffa DJ. Management of clinical stage IIIA primary lung<br />
cancers in the National Cancer Database. Ann Thorac Surg. 2014;98:424-32;<br />
discussion 32.<br />
Keywords: non small cell lung cancer, stage III, induction therapy<br />
ED10: LOCALLY ADVANCED NSCLC: STATE-OF-THE-ART TREATMENT<br />
TUESDAY, DECEMBER 6, 2016 - 16:00-17:30<br />
ED10.03 NEW DEVELOPMENTS IN RADIOTHERAPY OF STAGE III<br />
NSCLC<br />
Jacek Jassem<br />
Department of <strong>Oncology</strong> and Radiotherapy, Medical University of Gdansk, Gdansk/<br />
Poland<br />
NSCLC accounts for 80-85% of all lung cancers, and stage III disease<br />
constitutes about 40% of the total cases. The main treatment modality<br />
in these patients is radiotherapy, usually combined with concurrent<br />
chemotherapy. Five-year overall survival in stage III disease is merely 10-15%.<br />
Radiotherapy of thoracic tumors poses several challenges, such as tissue<br />
heterogeneity, tumor and organ motion and changing anatomy over the<br />
treatment course. Main approaches addressing these problems include<br />
dose intensification, altered fractionation and advanced radiotherapy<br />
techniques. Until recently, dose escalation was considered the main means<br />
to increase radiotherapy efficacy. Despite encouraging results of phase I–II<br />
studies, the results of recent RTOG trial 0617 were disappointing (1). This<br />
study compared high-dose radiotherapy (74 Gy/37 fractions) to a standarddose<br />
(60 Gy/30 fractions) concurrently with weekly paclitaxel/carboplatin,<br />
with or without cetuximab. Surprisingly, median overall survival in the<br />
high-dose arms was significantly shorter (20 months vs. 29 months in the<br />
standard-dose arms; p=0.004) (1). It was speculated that the inefficacy<br />
of high-dose radiotherapy could be due to long overall treatment time<br />
and accelerated tumor repopulation. Shortening treatment time may be<br />
accomplished by accelerated radiotherapy. A phase III study investigating<br />
continuous hyperfractionated accelerated radiotherapy (CHART; 54 Gy/36<br />
fractions of 1.5 Gy delivered 3 times daily over 12 consecutive days) showed<br />
increased efficacy compared to conventional fractionation (2). A CHARTWEL<br />
study, using the same fractionation but with weekend breaks, was not<br />
superior to conventional fractionation (3). A meta-analysis of 10 trials<br />
(2000 patients) demonstrated an absolute 5-year survival benefit of 2.5%<br />
with hyperfractionated and/or accelerated radiotherapy over conventional<br />
fractionation, at the expense of significantly increased grade 3–4 acute<br />
esophagitis (4). Important developments in lung radiotherapy represent new<br />
imaging techniques. PET-CT, currently a routine procedure, allows better<br />
patient selection for radical radiotherapy and facilitates selective irradiation<br />
of involved volumes (5). Image guided radiation therapy (IGRT), such as<br />
daily volumetric kilovoltage cone-beam computed tomography (CBCT),<br />
provides actual positional information, allowing for online repositioning<br />
and more precise tumor localization. Image-guided adaptive radiotherapy<br />
(IGART) additionally accounts for changes and deformations occurring<br />
during the radiotherapy course, thus allowing treatment re-planning (6).<br />
Currently, dose delivery in NSCLC is commonly accomplished by intensity<br />
modulated radiotherapy (IMRT). This technique improves the conformality<br />
of radiotherapy by modulating the radiation beam intensity profile,<br />
and allows decreasing the mean lung dose, particularly in patients with<br />
larger tumor volumes (7). The problem of intrafraction motion in thoracic<br />
malignancies has been traditionally managed by extension of treatment<br />
margins, leading to excessive radiation to normal tissues. Currently, tumor<br />
motion may be managed individually by respiratory-correlated 4-dimensional<br />
CT (4DCT) based on the acquisition of organ and tumor imaging data at<br />
extreme phases of the breathing cycle. An innovative option allowing for<br />
safe dose intensification is isotoxic therapy (8). This approach includes dose<br />
prescription defined by the maximal doses achievable to normal tissues.<br />
More recently, several clinical studies investigated the role of proton beam<br />
therapy in NSCLC. A dosimetric advantage of proton- over conventional<br />
photon radiotherapy is mediated by its unique properties: low doses upon<br />
tissue penetration, maximal dose deposition towards the end of the beam’s<br />
path (Bragg peak) and finite range with minimal dose beyond the tumor.<br />
Retrospective data and phase II studies suggested promising survival rates,<br />
and reduced pulmonary and esophageal toxicity with protons. However, the<br />
results of recent phase III trial did not confirm the superiority of this method<br />
over IMRT (9). In summary, recent diagnostic and therapeutic advances<br />
the use of radiation in stage III NSCLC allow for more accurate treatment<br />
planning, more precise dose delivery and managing tumor and organ motion.<br />
Some of these developments have been adopted in clinical practice, despite<br />
relatively few evidence of their advantages in terms of better local control and<br />
survival. The paucity of phase III trials testing new radiotherapy approaches<br />
is partly due to relying on better dose distribution and reduced exposure<br />
of normal tissues, making comparisons with less advanced techniques an<br />
ethical dilemma (10).References 1. Bradley JD, Paulus R, Komaki R, et al.<br />
Standard-dose versus high-dose conformal radiotherapy with concurrent<br />
and consolidation carboplatin plus paclitaxel with or without cetuximab<br />
for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a<br />
randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187-<br />
99. 2. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated<br />
accelerated radiotherapy (CHART) versus conventional radiotherapy in nonsmall-cell<br />
lung cancer: a randomised multicentre trial. Lancet 1997;350:161–5.<br />
3. Baumann M, Herrmann T, Koch R, et al. Final results of the randomized<br />
phase III CHARTWEL-trial (ARO 97–1) comparing hyperfractionatedaccelerated<br />
versus conventionally fractionated radiotherapy in non-small<br />
cell lung cancer (NSCLC). Radiother Oncol 2011;100:76–85. 4. Mauguen<br />
A, Le Pe´choux C, Saunders MI, et al. Hyperfractionated or accelerated<br />
radiotherapy in lung cancer: an individual patient data meta-analysis. J<br />
Clin Oncol 2012;30:2788–97. 5. Chang JY, Dong L, Liu H, et al. Image-guided<br />
radiation therapy for non-small cell lung cancer. J Thorac Oncol 2008;3:177–86.<br />
6. Sonke JJ, Belderbos J. Adaptive radiotherapy for lung cancer. Semin<br />
Radiat Oncol 2010;20:94-106. 7. Bezjak A, Rumble RB, Rodrigues G, and al.<br />
Intensity-modulated radiotherapy in the treatment of lung cancer. Clin<br />
Oncol 2012;24:508–20. 8. De Ruysscher D, van Baardwijk A, Steevens J, et<br />
al. Individualised isotoxic accelerated radiotherapy and chemotherapy are<br />
associated with improved long term survival of patients in stage III NSCLC: a<br />
prospective population-based study. Radither Oncol 2012;102:228-233. 9. ZX<br />
Liao, J. JJ Lee, R Komaki, et al. Bayesian randomized trial comparing intensity<br />
modulated radiation therapy versus passively scattered proton therapy for<br />
locally advanced non-small cell lung cancer. J Clin Oncol 2016;34(15S):435s. 10.<br />
Dziadziuszko R, Jassem J. Randomized clinical trials using new technologies<br />
in radiation oncology: ethical dilemma for medicine and science. J Thor Oncol<br />
2007;7:3-4.<br />
ED10: LOCALLY ADVANCED NSCLC: STATE-OF-THE-ART TREATMENT<br />
TUESDAY, DECEMBER 6, 2016 - 16:00-17:30<br />
ED10.04 NEW DEVELOPMENTS FOR SYSTEMIC THERAPIES IN<br />
STAGE III NSCLC<br />
Everett Vokes<br />
Medicine, University of Chicago, Chicago/IL/United States of America<br />
Concomitant chemoradiotherapy is currently the most widely accepted<br />
standard of care for patients with locoregionally advanced NSCLC. Induction<br />
chemotherapy represents an evidence-based alternative and is a particular<br />
attractive prior to surgery in patients with marginally resectable disease<br />
(1). Over the past two decades, the regimens of cisplatin and etoposide and<br />
carboplatin and paclitaxel with concurrent radiotherapy, respectively have<br />
been most widely used, with cisplatin and vinorelbine with radiotherapy as<br />
possible alternative. More recently interest in the cisplatin/pemetrexed/<br />
radiotherapy combination has gained interest based on the superior toxicity<br />
and efficacy profile of this regimen in the stage IV setting for patients with<br />
non-squamous cell malignancies (2). In addition, it is possible to administer<br />
this combination of drugs at systemic doses together with radiotherapy<br />
(3). In the randomized phase III PROCLAIM study, this regimen was directly<br />
compared with etoposide and cisplatin. The goal of this trial was to establish<br />
superiority of this regimen. The trial was closed prior to full enrollment with<br />
approximately 300 patients per arm evaluated, due to futility for superiority.<br />
Median survival for both study groups was very similar at 26.8 and 25.0<br />
months, respectively and better than statistically assumed (4). Additional<br />
chemoradiotherapy regiments of current interest include the addition of<br />
the PARP inhibitor veliparib to chemoradiotherapy as recently presented<br />
(5). Over the last decade, systemic therapy for patients with metastatic lung<br />
cancer has been transformed through the use of tumor mutation analyses and<br />
targeted therapies as well as the emergence of immune-oncology. However,<br />
application of these strategies to the stage III setting has been slow and no<br />
definitive data exist currently to support these strategies in the curative<br />
intent setting. The addition of cetuximab to chemoradiotherapy did not result<br />
S24 <strong>Journal</strong> of <strong>Thoracic</strong> <strong>Oncology</strong> • Volume 12 Issue S1 January 2017